Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin
Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announces 48-week clinical data from the Phase I clinical trial in China for its allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy AlloJoin™ for Knee Osteoarthritis (KOA). As quoted in the press release: … Continued
Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announces 48-week clinical data from the Phase I clinical trial in China for its allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy AlloJoin™ for Knee Osteoarthritis (KOA).
As quoted in the press release:
“We are very encouraged by the latest data from our AlloJoin™ Phase I trial in China which demonstrates good safety and early efficacy for the prevention of cartilage deterioration. The recent regulatory guidelines issued by the CFDA have set a clearer clinical and commercialization pathway for our AlloJoin™ platform. The success of the trial thus far, targeting an addressable market of 57 million KOA patients in China, prompted us to realign our resources to better focus on the China market. We believe developing our KOA therapies in China is a faster path to market at a fraction of the cost of conducting US trials,” said Tony (Bizuo) Liu, CEO for the Company.
Click here to read the full press release.
